Country: Malta
Language: English
Source: Medicines Authority
FACTOR VIII, HUMAN
Octapharma (IP) SPRL Alle de la Recherche 65, 1070 (Anderlecht), Belgium
B02BD02
FACTOR VIII, HUMAN 50 IU/ml
POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
FACTOR VIII, HUMAN 50 IU/ml
POM
ANTIHEMORRHAGICS
Authorised
2010-07-06
Page 1 of 9 _ _ PACKAGE LEAFLET: INFORMATION FOR THE USER OCTANATE 50 IU/ML POWDER AND SOLVENT FOR SOLUTION FOR INJECTION HUMAN COAGULATION FACTOR VIII OCTANATE 100 IU/ML POWDER AND SOLVENT FOR SOLUTION FOR INJECTION HUMAN COAGULATION FACTOR VIII READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Octanate is and what it is used for 2. What do you need to know before you use Octanate 3. How to use Octanate 4. Possible side effects 5. How to store Octanate 6. Contents of the pack and other information 1. WHAT OCTANATE IS AND WHAT IT IS USED FOR Octanate belongs to a group of medicines called clotting factors and contains human blood coagulation factor VIII. This is a special protein involved in blood clotting. Octanate is used to treat and prevent bleeding in patients with haemophilia A. This is a condition in which bleeding can go on for longer than expected. It is due to an hereditary lack of coagulation factor VIII in the blood. 2. WHAT DO YOU NEED TO KNOW BEFORE YOU USE OCTANATE It is strongly recommended that every time you receive a dose of Octanate the name and batch number of the product are recorded in order to maintain a record of the batches used. Your doctor may recommend that you consider vaccination against hepatitis A and B if you regularly or repeatedly receive human-derived Factor VIII products. DO NOT USE OCTANATE if you are allergic to human blood coagulation factor VIII or to any of the other ingredients of this medicine (listed in section 6). Page 2 of 9 _ _ WARN Read the complete document
_1/11 _ SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Octanate 50 IU/ml Powder and solvent for solution for injection Octanate 100 IU/ml Powder and solvent for solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Octanate 50 IU/ml Each vial contains nominally either 250 IU or 500 IU human coagulation factor VIII. The product contains approximately 50 IU* per ml human coagulation factor VIII when reconstituted with the supplied solvent (5 ml for 250 IU/vial and 10 ml for 500 IU/vial). The product contains approximately ≤ 30 IU per ml von Willebrand factor (VWF:RCo). Octanate 100 IU/ml Each vial contains nominally 1000 IU human coagulation factor VIII. The product contains approximately 100 IU* per ml human coagulation factor VIII when reconstituted with 10 ml of solvent. The product contains approximately ≤ 60 IU per ml von Willebrand factor (VWF:RCo). * The potency (IU) is determined using the European Pharmacopoeia chromogenic assay. The specific activity is ≥ 100 IU/mg protein. Produced from the plasma of human donors. Excipient with known effect: 250 IU/vial: less than 1 mmol sodium (23 mg) per dose, i.e. essentially `sodium-free` 500 IU/vial: Sodium up to 1.75 mmol (40 mg) per dose 1000 IU/vial: Sodium up to 1.75 mmol (40 mg) per dose Sodium concentration after reconstitution: 125 – 175 mmol/l For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder and solvent for solution for injection. The powder is white or pale yellow, also appearing as a friable solid. The solvent is a clear, colourless liquid. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Octanate can be used for all age groups. This preparation does not contain von Willebrand factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand’s disease. _2/11 _ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be under the supervision of a Read the complete document